Literature DB >> 32792350

Quality of ultrasonography reporting and factors associated with selection of imaging modality for uterine fibroids in Canada: results from a prospective cohort registry.

Olga Bougie1, Mohamed A Bedaiwy2, Philippe Laberge2, Gerald Lebovic2, Nicholas Leyland2, Mostafa Atri2, Ally Murji2.   

Abstract

BACKGROUND: Uterine fibroids are common in women and their management is heavily influenced by information gathered through imaging. We aimed to evaluate the type and quality of imaging performed for assessment of uterine fibroids in Canada.
METHODS: Starting in July 2015, premenopausal women with symptomatic fibroids were enrolled in a prospective, noninterventional, observational registry (Canadian Women With Uterine Fibroids Registry [CAPTURE]) that included 19 Canadian sites. Clinical characteristics were extracted from the baseline visit. We evaluated the association between demographic and clinical variables of interest with regard to imaging type using unadjusted and adjusted logistic regression models.
RESULTS: Of 1493 women, 1148 had ultrasonography, 135 had magnetic resonance imaging (MRI), 80 had other types of imaging and 130 did not have imaging reported within 12 months of the baseline visit. After adjusting for demographic and clinical characteristics, patients who underwent MRI had larger fibroids (odds ratio [OR] per 1-cm increase 1.11, 95% confidence interval [CI] 1.05-1.17) and more numerous fibroids (1 v. > 1; OR 1.74, 95% CI 1.14-2.64) compared with those who underwent ultrasonography only. For ultrasonography reporting, quality criteria were met for 268 of 1148 patients (23.3%). There was a difference in the quality of reporting among the 19 sites (p < 0.001). Logistic regression model accounting for within-site variability showed that reporting results from ultrasonography in the province of Quebec were less likely to meet all quality criteria (OR 0.20, 95% CI 0.06-0.66) and those from sites in more populated cities (≥ 400 000 inhabitants) were more likely to do so (OR 6.15, 95% CI 2.20-17.18).
INTERPRETATION: We determined that imaging modality for fibroids is associated with patient characteristics. The quality of reporting results for ultrasonography of fibroids in Canada falls short of internationally endorsed guidelines and needs improvement. STUDY REGISTRATION: ClinicalTrials.gov, no. NCT02580578. Copyright 2020, Joule Inc. or its licensors.

Entities:  

Mesh:

Year:  2020        PMID: 32792350      PMCID: PMC7850143          DOI: 10.9778/cmajo.20200004

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  16 in total

1.  Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group.

Authors:  T Van den Bosch; M Dueholm; F P G Leone; L Valentin; C K Rasmussen; A Votino; D Van Schoubroeck; C Landolfo; A J F Installé; S Guerriero; C Exacoustos; S Gordts; B Benacerraf; T D'Hooghe; B De Moor; H Brölmann; S Goldstein; E Epstein; T Bourne; D Timmerman
Journal:  Ultrasound Obstet Gynecol       Date:  2015-08-10       Impact factor: 7.299

2.  Further validation of the uterine fibroid symptom and quality-of-life questionnaire.

Authors:  Karin S Coyne; Mary Kay Margolis; Linda D Bradley; Richard Guido; G Larry Maxwell; James B Spies
Journal:  Value Health       Date:  2011-09-15       Impact factor: 5.725

3.  Ultrasound curricula in obstetrics and gynecology training programs.

Authors:  M Leonardi; A Murji; R D'Souza
Journal:  Ultrasound Obstet Gynecol       Date:  2018-08       Impact factor: 7.299

4.  Obstetric and gynecologic ultrasound curriculum and competency assessment in residency training programs: consensus report.

Authors:  Alfred Abuhamad; Katherine K Minton; Carol B Benson; Trish Chudleigh; Lori Crites; Peter M Doubilet; Rita Driggers; Wesley Lee; Karen V Mann; James J Perez; Nancy C Rose; Lynn L Simpson; Ann Tabor; Beryl R Benacerraf
Journal:  Am J Obstet Gynecol       Date:  2018-01       Impact factor: 8.661

Review 5.  Therapeutic management of uterine fibroid tumors: updated French guidelines.

Authors:  Henri Marret; Xavier Fritel; Lobna Ouldamer; Sofiane Bendifallah; Jean-Luc Brun; Isabelle De Jesus; Jean Derrien; Géraldine Giraudet; Vanessa Kahn; Martin Koskas; Guillaume Legendre; Jean Philippe Lucot; Julien Niro; Pierre Panel; Jean-Pierre Pelage; Hervé Fernandez
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2012-08-29       Impact factor: 2.435

6.  The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.

Authors:  James B Spies; Karin Coyne; Noureddine Guaou Guaou; Deneane Boyle; Kerry Skyrnarz-Murphy; Sheila M Gonzalves
Journal:  Obstet Gynecol       Date:  2002-02       Impact factor: 7.661

7.  The management of uterine leiomyomas.

Authors:  George A Vilos; Catherine Allaire; Philippe-Yves Laberge; Nicholas Leyland
Journal:  J Obstet Gynaecol Can       Date:  2015-02

8.  Assessment of patients with menorrhagia: how valid is a structured clinical history as a measure of health status?

Authors:  D A Ruta; A M Garratt; Y C Chadha; G M Flett; M H Hall; I T Russell
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

9.  Influence of Ethnicity on Clinical Presentation and Quality of Life in Women With Uterine Fibroids: Results From a Prospective Observational Registry.

Authors:  Ally Murji; Mohamed Bedaiwy; Sukhbir Sony Singh; Olga Bougie
Journal:  J Obstet Gynaecol Can       Date:  2019-12-25

10.  A Patient Registry for the Management of Uterine Fibroids in Canada: Protocol for a Multicenter, Prospective, Noninterventional Study.

Authors:  Mohamed A Bedaiwy; Peter Janiszewski; Sukhbir S Singh
Journal:  JMIR Res Protoc       Date:  2018-11-20
View more
  1 in total

1.  A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids.

Authors:  Nicholas Leyland; Mathew Leonardi; Ally Murji; Sukhbir S Singh; Ayman Al-Hendy; Linda Bradley
Journal:  Reprod Sci       Date:  2022-02-17       Impact factor: 3.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.